# Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

> **NCT07315113** · PHASE1 · RECRUITING · sponsor: **Nuvectis Pharma, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- EGFR Mutation Positive Non-small Cell Lung Cancer
- EGFR Mutated Non-small Cell Lung Cancer Patients

## Interventions

- **DRUG:** NXP900
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07315113
- **Lead sponsor:** Nuvectis Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07315113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07315113, "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07315113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*